share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/08/31 03:53

Moomoo AI 已提取核心訊息

TC BioPharm completed an upsized public offering on August 29, 2024, raising $6 million in gross proceeds. The offering included 53,558 American Depositary Shares (ADSs), pre-funded warrants to purchase up to 5,946,442 ADSs, and series H warrants to purchase up to 6,000,000 ADSs, priced at $1.00 per ADS and associated warrant.The Series H Warrants are immediately exercisable with a one-year expiration period and an exercise price of £0.76 ($1.00) per ADS. The pre-funded warrants are exercisable at $0.001 per ADS until fully exercised. Each ADS represents 200 ordinary shares of the company.The proceeds will support TC BioPharm's upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, market awareness initiatives, and ongoing operational expenses. The offering was conducted under an effective registration statement filed with the SEC on Form F-1.
TC BioPharm completed an upsized public offering on August 29, 2024, raising $6 million in gross proceeds. The offering included 53,558 American Depositary Shares (ADSs), pre-funded warrants to purchase up to 5,946,442 ADSs, and series H warrants to purchase up to 6,000,000 ADSs, priced at $1.00 per ADS and associated warrant.The Series H Warrants are immediately exercisable with a one-year expiration period and an exercise price of £0.76 ($1.00) per ADS. The pre-funded warrants are exercisable at $0.001 per ADS until fully exercised. Each ADS represents 200 ordinary shares of the company.The proceeds will support TC BioPharm's upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, market awareness initiatives, and ongoing operational expenses. The offering was conducted under an effective registration statement filed with the SEC on Form F-1.
TC BioPharm於2024年8月29日完成了一次擴大規模的公開發行，籌集了600萬美金的總收入。此次發行包括53,558股美國存托股票（ADS），預先資助的Warrants可購買最多5,946,442股ADS，以及系列H Warrants可購買最多6,000,000股ADS，價格爲每股ADS和相關Warrants 1.00美元。系列H Warrants可立即行使，具有一年的到期期限，行使價格爲每股ADS 0.76英鎊（1.00美元）。預先資助的Warrants可在每股ADS 0.001美元的價格行使，直到完全行使。每股ADS代表公司200股普通股。募集資金將用於支持TC BioPharm即將進行的臨牀試驗，重點關注復發/難治性急性髓性白血病、市場意識提升計劃以及持續的運營費用。此次發行是在向SEC提交的有效註冊聲明的基礎上進行的，採用F-1表格。
TC BioPharm於2024年8月29日完成了一次擴大規模的公開發行，籌集了600萬美金的總收入。此次發行包括53,558股美國存托股票（ADS），預先資助的Warrants可購買最多5,946,442股ADS，以及系列H Warrants可購買最多6,000,000股ADS，價格爲每股ADS和相關Warrants 1.00美元。系列H Warrants可立即行使，具有一年的到期期限，行使價格爲每股ADS 0.76英鎊（1.00美元）。預先資助的Warrants可在每股ADS 0.001美元的價格行使，直到完全行使。每股ADS代表公司200股普通股。募集資金將用於支持TC BioPharm即將進行的臨牀試驗，重點關注復發/難治性急性髓性白血病、市場意識提升計劃以及持續的運營費用。此次發行是在向SEC提交的有效註冊聲明的基礎上進行的，採用F-1表格。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！